A Landmark Trial for Vascular Aging

The pursuit of longevity has long focused on cellular senescence, telomere length, and epigenetic reprogramming. But a new randomized controlled trial published in the European Heart Journal Open on November 4, 2026, shifts the spotlight to an equally critical dimension of aging: the health of our blood vessels. The STAMINA study, conducted at the University of Surrey with the Royal Surrey NHS Foundation Trust, demonstrates that a daily multi-ingredient nutritional supplement can significantly improve vascular function, reduce arterial stiffness, and lower systolic blood pressure in healthy adults aged 40 and older — all within six months.

Vascular aging is one of the earliest and most pervasive manifestations of biological decline. As arteries stiffen and endothelial function deteriorates, the risk of cardiovascular disease, stroke, and cognitive impairment rises sharply. The STAMINA trial represents one of the first rigorously controlled human studies to show that a nutritional intervention can measurably reverse these age-related vascular changes, offering a potentially accessible approach to extending not just lifespan but healthspan.

The STAMINA Study Design

STAMINA — formally titled Effects of a Supplement to Target Ageing Mechanisms on Vascular Function — was a single-center, randomized, double-blind, placebo-controlled trial registered as NCT06145087. The study enrolled 61 apparently healthy, non-smoking adults aged 40 and older. Participants were randomly assigned to receive either NOVOS Core, a multi-component nutritional powder supplement, or an identical-looking placebo, taken once daily for six months.

The supplement contains 12 ingredients selected for their complementary effects on established aging pathways: vitamin C, magnesium malate, calcium alpha-ketoglutarate, glycine, GreenGrown glucosamine sulphate, Rhodiola rosea root extract, L-theanine, hyaluronic acid, fisetin, organic ginger root extract, pterostilbene, and lithium aspartate. Of the 61 enrollees, 43 participants completed both study visits and were included in the primary analysis.

Researchers assessed three primary vascular health markers: flow-mediated dilation (FMD) as a measure of endothelial function, carotid-femoral pulse wave velocity (PWV) as an indicator of arterial stiffness, and systolic blood pressure. Measurements were taken at baseline, within one hour of the first dose, and again after six months of daily supplementation.

Key Findings: Rapid and Sustained Improvements

The results were striking on multiple fronts. Endothelial function, measured as flow-mediated dilation, increased by 47 percent from baseline in the supplement group. The adjusted improvement versus placebo was 2.9 percent — a magnitude considered clinically meaningful in published vascular research. Remarkably, this improvement was detectable within just one hour of the first dose, suggesting that some ingredients exert immediate effects on vascular tone.

Arterial stiffness, measured via pulse wave velocity, decreased in the supplement group while increasing in the placebo group over the same period. The between-group difference of 1.18 meters per second is especially significant given that PWV typically rises by approximately 1.0 meter per second per decade across adulthood. In practical terms, this difference translates to reversing several years of vascular aging.

Systolic blood pressure decreased by 6.1 mmHg more in the supplement group compared to placebo after six months. This reduction was reflected in a modest decrease in estimated 10-year cardiovascular risk. Diastolic blood pressure did not differ significantly between groups, and no changes in blood lipid levels were observed during the trial.

Why Vascular Aging Matters for Longevity

Cardiovascular disease remains the leading cause of death worldwide, and vascular aging is its foundational precursor. The endothelium — the thin membrane lining the interior of blood vessels — regulates vascular tone, inflammation, thrombosis, and smooth muscle proliferation. When endothelial function declines, arteries become stiffer, blood pressure rises, and the stage is set for atherosclerosis, heart attack, and stroke.

What makes the STAMINA findings particularly relevant to longevity science is the multi-pathway approach. Rather than targeting a single mechanism, the supplement’s 12 ingredients address several interconnected aging processes simultaneously:

• Cellular senescence: Fisetin, a naturally occurring flavonoid, has senolytic properties that help eliminate “zombie cells” — senescent cells that accumulate with age and secrete inflammatory compounds damaging surrounding tissue.
• Oxidative stress: Vitamin C, pterostilbene, and ginger root extract provide antioxidant support to counter the cumulative damage from reactive oxygen species that accelerates vascular aging.
• Metabolic function: Calcium alpha-ketoglutarate and magnesium malate support mitochondrial energy production and metabolic homeostasis, both of which decline with age.
• Stress resilience: Rhodiola rosea and L-theanine modulate the stress response, potentially reducing cortisol-driven vascular damage.
• Structural integrity: Hyaluronic acid and glucosamine support connective tissue and vascular wall structure.
• Epigenetic regulation: Lithium aspartate, in micro-doses, has been associated with neuroprotective and potentially epigenetic effects.

The Fisetin Connection

The inclusion of fisetin is particularly noteworthy. A flavonoid found in strawberries and apples, fisetin has gained attention in longevity research for its ability to selectively induce apoptosis in senescent cells. Multiple clinical trials have investigated fisetin for conditions ranging from chronic kidney disease to osteoarthritis and frailty. The STAMINA study suggests that even modest doses of fisetin, when combined with complementary compounds, may contribute to measurable vascular improvements in a relatively short timeframe.

Limitations and the Path Forward

Despite the encouraging results, the STAMINA study has important limitations that the researchers themselves acknowledge. The trial involved only 61 participants at a single center — a relatively small sample that may not capture variations across broader populations. Larger multi-center trials will be needed to confirm whether the findings generalize.

Second, the study assessed cardiovascular biomarkers rather than clinical outcomes. Improvements in endothelial function, arterial stiffness, and blood pressure do not automatically translate into fewer heart attacks or strokes. Long-term studies tracking actual cardiovascular events will be essential to establish clinical benefit.

Third, because the supplement contains 12 ingredients, the study cannot determine which specific compound — or combination of compounds — is responsible for the observed effects. Future research with isolated ingredients and targeted combinations will help clarify the mechanisms at play.

Finally, the final measurements were taken approximately 24 hours after the last dose, meaning the study cannot distinguish lasting vascular changes from residual effects of recent supplementation. Whether the benefits persist after discontinuation remains an open question.

Implications for Everyday Longevity

For individuals interested in practical longevity interventions, the STAMINA trial offers both encouragement and caution. On one hand, it demonstrates that a carefully formulated nutritional supplement can produce measurable improvements in vascular aging markers — the kind of changes that, if sustained, could meaningfully reduce cardiovascular risk over time. The 6.1 mmHg reduction in systolic blood pressure, for context, is comparable to the effect of many prescription antihypertensive medications.

On the other hand, the study underscores that no single supplement is a magic bullet. Vascular health is determined by a complex interplay of genetics, diet, exercise, sleep, stress, and environmental factors. A supplement may support these foundational pillars, but it cannot replace them. The most robust longevity strategies remain holistic: regular physical activity, a nutrient-dense diet, adequate sleep, stress management, and avoidance of smoking and excessive alcohol.

The STAMINA study also highlights a growing trend in longevity science: the shift from single-target interventions to multi-pathway approaches. Just as combination therapies have transformed cancer and HIV treatment, the future of anti-aging medicine may lie in carefully designed combinations that address the interconnected hallmarks of aging simultaneously. This trial provides an early proof of concept that such an approach can work in humans, not just in mice.

The Broader Landscape of Longevity Science in 2026

The STAMINA trial arrives amid a surge of longevity research. In the same week, Immorta Bio announced the first human administration of SenoMune-0257, an immunotherapy designed to help the immune system recognize and eliminate senescent cells. Nature Aging published a study identifying vanadyl sulfate as a senolytic agent that extends lifespan in male mice by exploiting a redox-proteostasis vulnerability unique to senescent cells. And researchers continue to explore NAD+ metabolism, SIRT1 activation, and epigenetic reprogramming as complementary pathways to extend healthspan.

What ties these developments together is a shared recognition: aging is not a single process but a network of interconnected biological changes. Interventions that target multiple nodes in this network — whether through combination supplements, senolytic immunotherapy, or metabolic modulation — may prove more effective than single-molecule approaches. The STAMINA study, with its 12-ingredient formulation, exemplifies this multi-target philosophy in action.

As the field advances, the distinction between lifespan and healthspan becomes increasingly central. Living longer matters only if those additional years are spent in good health. Vascular health is a cornerstone of that equation — it determines not only cardiovascular risk but also cognitive function, kidney health, and physical mobility. A supplement that can measurably improve vascular aging markers in six months represents a meaningful step toward making healthspan extension a practical reality rather than a theoretical promise.

The road from biomarker improvements to proven clinical outcomes is long, and the STAMINA researchers are appropriately cautious about overinterpreting their findings. But for a field that has seen far more promise in animal models than in human trials, this study marks a welcome and necessary transition — from the laboratory bench to the everyday lives of people who want to age well.

---

Edited by Palawan @QUE.COM
Website: https://QUE.COM Intelligence
Sponsored by: https://MAJ.COM AI Autonomous